References
- Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995 Feb; 49(2): 280–94. doi:10.2165/00003495-199549020-00010.
- Kane SP. Venlafaxine Hydrochloride - Drug Usage Statistics [Internet]. Clin Calc. 2017;[cited 2019 Mar 4]. Available from http://clincalc.com/DrugStats/Drugs/VenlafaxineHydrochloride.
- Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23;354(12):1231–42. doi:10.1056/NEJMoa052963.
- White CM, Gailey RA, Levin GM, Smith T. Seizure resulting from a venlafaxine overdose. Ann Pharmacother. 1997 Feb; 31(2): 178–80. doi:10.1177/106002809703100209.
- Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007 Aug; 64(2): 192–97. doi:10.1111/bcp.2007.64.issue-2.
- Khalifa M, Daleau P, Turgeon AJ. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999 Oct;291(1):280–84.
- Sattar SP, Grant KM, Bhatia SC. A case of venlafaxine abuse. N Engl J Med. 2003 Feb 20;348(8):764–65. doi:10.1056/NEJMicm020037.
- Quaglio G, Schifano F, Lugoboni F. Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. Addiction. 2008 Sep; 103(9): 1572–74. doi:10.1111/j.1360-0443.2008.02351.x.
- Namdari B. Venlafaxine abuse in a patient with schizophrenia and prior history of substance dependence: a case report. J Addict Dis. 2013 Oct; 32(4): 393–95. doi:10.1080/10550887.2013.849974.
- Francesconi G, Orsolini L, Papanti D, Corkery JM, Schifano F. Venlafaxine as the “baby ecstasy?” Literature overview and analysis of web-based misusers′ experiences. Hum Psychopharmacol Clin Exp. 2015 Jul 28;30(4):255–61. doi:10.1002/hup.v30.4.
- Schifano F, Chiappini S. Is there a potential of misuse for venlafaxine and bupropion? Front Pharmacol. 2018;9:239. doi:10.3389/fphar.2018.00239.
- American Association of Poison Control Centers (AAPCC). National Poison Data System (NPDS) NPDS Coding Users‘ Manual Version 3.2. AAPCC. 2016 Feb pp. 1–98.
- United States Census Bureau. Population Distribution and Change: 2000 to 2010 [Internet]. Census.gov. 2011 [cited 2018 Oct 22]. Available from: https://www.census.gov/prod/cen2010/briefs/c2010br-01.pdf
- Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med. 2017 Jan; 69(1): 73–78. doi:10.1016/j.annemergmed.2016.08.444.
- Stassinos GL, Klein-Schwartz W. Bupropion “Abuse” reported to US poison centers. J Addict Med. 2016;10(5):357–62. doi:10.1097/ADM.0000000000000249.
- Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: diversion rates and qualitative research findings. Pharmacoepidem Drug Safe. 2017 May 10;26(9):1083–86. doi:10.1002/pds.4230.
- Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse — proactive pharmacovigilance. N Engl J Med. 2018 Jul 19;379(3):205–07. doi:10.1056/NEJMp1806486.
- Song J-H, Yu B-H, Lee D, Yoon SC, Jeon HJ. Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder. Psychiatry Investig. 2011;8(1):74–3. doi:10.4306/pi.2011.8.1.74.
- Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci. 2007 Feb; 32(1): 97–101. doi:10.2131/jts.32.97.
- Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(4):315–32. doi:10.1080/15563650701285289.
- Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 annual report of the american association of poison control centers’ national poison data system (NPDS): 34th annual report. Clin Toxicol (Phila). 2017 Jun 23;55(10):1072–254. doi:10.1080/15563650.2017.1388087.